CO2023017609A2 - Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso - Google Patents

Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso

Info

Publication number
CO2023017609A2
CO2023017609A2 CONC2023/0017609A CO2023017609A CO2023017609A2 CO 2023017609 A2 CO2023017609 A2 CO 2023017609A2 CO 2023017609 A CO2023017609 A CO 2023017609A CO 2023017609 A2 CO2023017609 A2 CO 2023017609A2
Authority
CO
Colombia
Prior art keywords
antibodies
multispecific
cea
methods
antibody
Prior art date
Application number
CONC2023/0017609A
Other languages
English (en)
Spanish (es)
Inventor
Liang Qu
Tong Zhang
Zhuo Li
Xin Chen
Lin Zhu
Penghao Wang
Xiaosui Zhou
Yuanyuan Xie
Jie Li
Jian Sun
Jing Song
Xuehui Li
Original Assignee
Beigene Switzerland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Switzerland Gmbh filed Critical Beigene Switzerland Gmbh
Publication of CO2023017609A2 publication Critical patent/CO2023017609A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2023/0017609A 2021-05-21 2023-12-15 Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso CO2023017609A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2021095113 2021-05-21
CN2022085625 2022-04-07
CN2022088172 2022-04-21
PCT/CN2022/093565 WO2022242680A1 (en) 2021-05-21 2022-05-18 Anti-cea and anti-cd137 multispecific antibodies and methods of use

Publications (1)

Publication Number Publication Date
CO2023017609A2 true CO2023017609A2 (es) 2024-01-15

Family

ID=84140249

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0017609A CO2023017609A2 (es) 2021-05-21 2023-12-15 Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso

Country Status (12)

Country Link
US (1) US20240190989A1 (enExample)
EP (1) EP4340805A4 (enExample)
JP (1) JP2024522075A (enExample)
KR (1) KR20240014058A (enExample)
CN (1) CN117396182A (enExample)
AU (1) AU2022277479A1 (enExample)
CA (1) CA3219672A1 (enExample)
CO (1) CO2023017609A2 (enExample)
IL (1) IL308660A (enExample)
MX (1) MX2023013726A (enExample)
TW (1) TW202307003A (enExample)
WO (1) WO2022242680A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202434306A (zh) * 2022-11-24 2024-09-01 瑞士商百濟神州瑞士有限責任公司 抗ｃｅａ抗體藥物軛合物及使用方法
CN116814664B (zh) * 2023-08-25 2023-12-12 中国医学科学院肿瘤医院 一种扩展肿瘤识别表位的cea嵌合抗原受体t细胞的制备与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3199552T (pt) * 2012-11-20 2020-03-25 Sanofi Sa Anticorpos anti-ceacam5 e suas utilizações
ES2788979T3 (es) * 2014-11-14 2020-10-23 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
WO2016144976A1 (en) * 2015-03-09 2016-09-15 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
CN105753978B (zh) * 2016-03-14 2020-02-07 中国人民解放军第二军医大学 一种hla-a11限制性癌胚抗原来源的表位肽及用途
CA3047070A1 (en) * 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
TWI841551B (zh) * 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
BR112021026293A2 (pt) * 2019-06-26 2022-03-03 Hoffmann La Roche Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula

Also Published As

Publication number Publication date
TW202307003A (zh) 2023-02-16
IL308660A (en) 2024-01-01
CA3219672A1 (en) 2022-11-24
KR20240014058A (ko) 2024-01-31
WO2022242680A1 (en) 2022-11-24
US20240190989A1 (en) 2024-06-13
CN117396182A (zh) 2024-01-12
MX2023013726A (es) 2024-02-13
AU2022277479A1 (en) 2024-01-18
EP4340805A4 (en) 2026-01-14
JP2024522075A (ja) 2024-06-11
EP4340805A1 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
CO2023004252A2 (es) Anticuerpos anti-ceacam5 y conjugados y usos de los mismos
CL2020002305A1 (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1
MX2025000370A (es) Anticuerpos anti-ctla4 y metodos para elaborarlos y usarlos
MX2020008184A (es) Receptores de antigeno quimericos dirigidos a cd70.
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
BR112016020752A2 (pt) ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente?
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
MX2019011101A (es) Anticuerpo que se une especificamente a muc1 y uso del mismo.
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
MX2023011121A (es) Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos.
BR112016024214B8 (pt) Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
MX2021000783A (es) Anticuerpos humanizados contra psma.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2025002301A2 (es) Anticuerpos anti-ccr8 y métodos de uso
MX2025004652A (es) Conjugados de farmaco-anticuerpo del cumulo de diferenciacion (cd70) y metodos de uso de los mismos
CO2025008154A2 (es) Conjugados anticuerpo–fármaco anti–cea y métodos de uso
MX2020010110A (es) Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.
MX2023013726A (es) Anticuerpos multiespecificos anti-cea y anti-cd137 y metodos de uso.
MX2025001086A (es) Construcciones de anticuerpos multivalentes y bispecificos y metodos de uso de los mismos
AR077941A1 (es) Anticuerpos contra osteopontina
CL2025001474A1 (es) Anticuerpos anti-cd137 y métodos de uso
CL2022000107A1 (es) Anticuerpos anti-grp78 y método de uso de los mismos